chronic obstructive pulmonary disease, hypertension
Conditions
Interventions
administration of bisoprolol, increased from 1.25mg/day to 2.5mg at a month intervals up to 5mg if tolerated. It will be continued after the end of this study unless the patient want to discontinue o
Sponsors
Okayama University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) patients with chronic obstructive pulmonary disease (2) a postbronchodilator FEV1(forced expiratory volume) of 70% or less of the FVC(forced vital capacity) (3) a postbronchodilator FEV1 of 80% or less of the predicted value (4) an age of 40 years or more (5) 10 pack-years smoking history (6) hypertension (7) adequate organ function
Exclusion criteria
Exclusion criteria: (1) patients with severe (NYHA grade 3 or 4) cardiac failure (2) left ventricular contractility of 40% or less (3) 2nd/3rd-degree atrioventricular block, sinoatrial block or sick sinus syndrome (4) variant angina pectoris (5) severe peripheral circulatory disturbance (6) pulmonary hypertension from right cardiac failure (7) a history of pulmonary resection (8) malignancy of disease-free interval of less than 3 years (9) systolic blood pressure of less than 100 mmHg (10) cardiac rate of less than 60 bpm on a constant basis (11) uncontrolled diabetic mellitus (12) thyrotoxicosis (13) pheochromocytoma (14) psoriasis (15) use of supplemental oxygen or with SpO2 of less than 90%(or PaO2 of less than 60 Torr) (16) asthma (17) active interstitial pneumonia (18) COPD exacerbation or respiratory infection within 4 weeks before registration (19) pregnant women (20) current use of beta-blocker (21) history of hypersensitivity to bisoprolol (22) patients considered to be inappropriate for this study by attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate of acute exacerbation (moderate or more) | — |
Countries
Japan
Contacts
Public ContactAkihiko Taniguchi
Okayama University Health Service Center
Outcome results
None listed